Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1982 1
1983 1
1985 2
1986 1
1987 2
1988 2
1989 2
1990 1
1991 3
1992 1
1996 2
1998 4
1999 1
2000 3
2001 9
2002 15
2003 5
2004 7
2005 9
2006 8
2007 27
2008 34
2009 42
2010 54
2011 68
2012 89
2013 111
2014 135
2015 156
2016 182
2017 150
2018 175
2019 155
2020 163
2021 173
2022 191
2023 204
2024 88

Text availability

Article attribute

Article type

Publication date

Search Results

1,953 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine.
[No authors listed] [No authors listed] 2021 Jul 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Jul 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000018 Free Books & Documents. Review.
No information is available on the use of bendamustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as bendamustine.[1] Based on the half-life of the dr …
No information is available on the use of bendamustine during breastfeeding. Most sources consider breastfeeding to be contraindicate …
Bendamustine.
[No authors listed] [No authors listed] 2017 Sep 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Sep 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643438 Free Books & Documents. Review.
Bendamustine is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of chronic lymphocytic leukemia and refractory forms of non-Hodgkin lymphoma. ...Bendamustine also has potent immunosuppressi …
Bendamustine is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the tr …
Bendamustine and pneumocystis pneumonia: A systematic review.
Hakamifard A, Mardani M, Nasiri MJ, Gholipur-Shahraki T. Hakamifard A, et al. Health Sci Rep. 2022 Apr 26;5(3):e610. doi: 10.1002/hsr2.610. eCollection 2022 May. Health Sci Rep. 2022. PMID: 35509412 Free PMC article. Review.
BACKGROUND: Bendamustine, a bifunctional mechlorethamine alkylating agent, is used in the treatment of patients with hematologic malignancies. ...The used keywords included "Pneumonia, Pneumocystis"or "Pneumocystis Pneumonia"or "Pneumocystis jirovecii" and "Bendamustine …
BACKGROUND: Bendamustine, a bifunctional mechlorethamine alkylating agent, is used in the treatment of patients with hematologic mali …
Bendamustine.
Balfour JA, Goa KL. Balfour JA, et al. Drugs. 2001;61(5):631-8; discussion 639-40. doi: 10.2165/00003495-200161050-00009. Drugs. 2001. PMID: 11368287 Review.
Bendamustine is a bifunctional alkylating agent with cytotoxic activity against human ovarian and breast cancers in vitro. ...Bendamustine has a relatively low propensity to induce alopecia....
Bendamustine is a bifunctional alkylating agent with cytotoxic activity against human ovarian and breast cancers in vitro. ...Bend …
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Sehn LH, et al. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23. Lancet Oncol. 2016. PMID: 27345636 Clinical Trial.
Grade 3-5 adverse events occurred in 132 (68%) of 194 patients in the obinutuzumab plus bendamustine group and in 123 (62%) of 198 patients in the bendamustine monotherapy group. ...Three (25%) of 12 adverse event-related deaths in the obinutuzumab plus bendamust …
Grade 3-5 adverse events occurred in 132 (68%) of 194 patients in the obinutuzumab plus bendamustine group and in 123 (62%) of 198 pa …
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G, Navarro V, Martín-López AÁ, Rejeski K, Kwon M, Jalowiec KA, Amat P, Reguera-Ortega JL, Gallur L, Blumenberg V, Gutiérrez-Herrero S, Roddie C, Benzaquén A, Delgado-Serrano J, Sánchez-Salinas MA, Bailén R, Carpio C, López-Corral L, Hernani R, Bastos M, O'Reilly M, Martín-Martín L, Subklewe M, Barba P. Iacoboni G, et al. J Clin Oncol. 2024 Jan 10;42(2):205-217. doi: 10.1200/JCO.23.01097. Epub 2023 Oct 24. J Clin Oncol. 2024. PMID: 37874957
Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propens …
Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies …
Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A. Lalic H, et al. Oncol Rep. 2022 Jun;47(6):114. doi: 10.3892/or.2022.8325. Epub 2022 May 4. Oncol Rep. 2022. PMID: 35506458 Free PMC article. Review.
Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. ...In the present review, the current knowledge on the use of bendamustine in oncology, its pharmacokinetics, mechanism of action and tox …
Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. ...I …
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
Ghilardi G, Chong EA, Svoboda J, Wohlfarth P, Nasta SD, Williamson S, Landsburg JD, Gerson JN, Barta SK, Pajarillo R, Myers J, Chen AI, Schachter L, Yelton R, Ballard HJ, Hodges Dwinal A, Gier S, Victoriano D, Weber E, Napier E, Garfall A, Porter DL, Jäger U, Maziarz RT, Ruella M, Schuster SJ. Ghilardi G, et al. Ann Oncol. 2022 Sep;33(9):916-928. doi: 10.1016/j.annonc.2022.05.521. Epub 2022 Jun 9. Ann Oncol. 2022. PMID: 35690221 Free article.
We observed significant differences, however, in the frequency and severity of adverse events. In particular, patients treated with bendamustine had lower rates of cytokine release syndrome and neurotoxicity. ...Fewer episodes of infection, neutropenic fever, and post-infu …
We observed significant differences, however, in the frequency and severity of adverse events. In particular, patients treated with benda …
Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials.
Gafter-Gvili A, Gurion R, Raanani P, Shpilberg O, Vidal L. Gafter-Gvili A, et al. Hematol Oncol. 2017 Dec;35(4):424-431. doi: 10.1002/hon.2350. Epub 2016 Oct 13. Hematol Oncol. 2017. PMID: 27734524 Review.
There was no increase in the rate of grade 3 to 4 neutropenia in the bendamustine arm (RR 0.84 [95% CI, 0.63-1.12]). Our systematic review demonstrates no effect of bendamustine on the rate of infections when compared with either alkylating agents or fludarabine. Th …
There was no increase in the rate of grade 3 to 4 neutropenia in the bendamustine arm (RR 0.84 [95% CI, 0.63-1.12]). Our systematic r …
Bendamustine in multiple myeloma.
Gentile M, Vigna E, Recchia AG, Morabito L, Mendicino F, Giagnuolo G, Morabito F. Gentile M, et al. Eur J Haematol. 2015 Nov;95(5):377-88. doi: 10.1111/ejh.12609. Epub 2015 Jul 14. Eur J Haematol. 2015. PMID: 26085055 Review.
Moreover, bendamustine has been successfully used as conditioning for autologous stem-cell transplantation. Finally, the use of bendamustine does not compromise peripheral blood stem-cell collection. ...
Moreover, bendamustine has been successfully used as conditioning for autologous stem-cell transplantation. Finally, the use of be …
1,953 results